VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-stra...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Report |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | Enterlein, Sven Warfield, Kelly L Swenson, Dana L Stein, David A Smith, Jeffrey L Gamble, C S Kroeker, Andrew D Iversen, Patrick L Bavari, Sina Muehlberger, Elke |
description | Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
Pub. in Antimicrobial Agents and Chemotherapy,v50 n3, p984-993, Mar 2006. |
format | Report |
fullrecord | <record><control><sourceid>dtic_1RU</sourceid><recordid>TN_cdi_dtic_stinet_ADA443616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ADA443616</sourcerecordid><originalsourceid>FETCH-dtic_stinet_ADA4436163</originalsourceid><addsrcrecordid>eNqFi70KwjAURrM4iPoGDvcFHCS1e9CKokIH6RrS_NiL8UaaK76-EdydPjjnfFOhu1Zu4ETJ3l16ExxpwB45Q9OnaKDD8ZVBPZ4RA1rDmAgMOWjHxN6WTN0MUmY4ex5MLPdQ8LdCggtaPxeTYGL2i9_OxHLfXLeHlWO0OjOSZ612qqpkva7lH_0Ba0Y4wA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice</title><source>DTIC Technical Reports</source><creator>Enterlein, Sven ; Warfield, Kelly L ; Swenson, Dana L ; Stein, David A ; Smith, Jeffrey L ; Gamble, C S ; Kroeker, Andrew D ; Iversen, Patrick L ; Bavari, Sina ; Muehlberger, Elke</creator><creatorcontrib>Enterlein, Sven ; Warfield, Kelly L ; Swenson, Dana L ; Stein, David A ; Smith, Jeffrey L ; Gamble, C S ; Kroeker, Andrew D ; Iversen, Patrick L ; Bavari, Sina ; Muehlberger, Elke ; PHILIPPS UNIV MARBURG (GERMANY)</creatorcontrib><description>Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
Pub. in Antimicrobial Agents and Chemotherapy,v50 n3, p984-993, Mar 2006.</description><language>eng</language><subject>AMPLIFICATION ; ANALOGS ; ANATOMICAL MODELS ; Anatomy and Physiology ; ANTISENSE THERAPY ; ANTIVIRAL ; ARBOVIRUSES ; CELLS(BIOLOGY) ; CHEMICAL AGENTS ; CULTURES(BIOLOGY) ; DEOXYRIBONUCLEIC ACIDS ; DOSAGE ; EBOLA VIRUS ; EFFICACY ; FILOVIRUS ; INFECTIOUS DISEASES ; LABORATORY ANIMALS ; LETHALITY ; MARBURG ; Medicine and Medical Research ; MICE ; Microbiology ; MORPHOLINE ; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS ANTISENSE PHOSPHORODIAMIDATE OLIGOMERS ; PMO(PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS) ; PROTECTION ; RINGS ; THERAPY ; VACCINES ; VIRUSES</subject><creationdate>2006</creationdate><rights>Approved for public release; distribution is unlimited. This document is not available from DTIC in microfiche.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,780,885,27567,27568</link.rule.ids><linktorsrc>$$Uhttps://apps.dtic.mil/sti/citations/ADA443616$$EView_record_in_DTIC$$FView_record_in_$$GDTIC$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Enterlein, Sven</creatorcontrib><creatorcontrib>Warfield, Kelly L</creatorcontrib><creatorcontrib>Swenson, Dana L</creatorcontrib><creatorcontrib>Stein, David A</creatorcontrib><creatorcontrib>Smith, Jeffrey L</creatorcontrib><creatorcontrib>Gamble, C S</creatorcontrib><creatorcontrib>Kroeker, Andrew D</creatorcontrib><creatorcontrib>Iversen, Patrick L</creatorcontrib><creatorcontrib>Bavari, Sina</creatorcontrib><creatorcontrib>Muehlberger, Elke</creatorcontrib><creatorcontrib>PHILIPPS UNIV MARBURG (GERMANY)</creatorcontrib><title>VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice</title><description>Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
Pub. in Antimicrobial Agents and Chemotherapy,v50 n3, p984-993, Mar 2006.</description><subject>AMPLIFICATION</subject><subject>ANALOGS</subject><subject>ANATOMICAL MODELS</subject><subject>Anatomy and Physiology</subject><subject>ANTISENSE THERAPY</subject><subject>ANTIVIRAL</subject><subject>ARBOVIRUSES</subject><subject>CELLS(BIOLOGY)</subject><subject>CHEMICAL AGENTS</subject><subject>CULTURES(BIOLOGY)</subject><subject>DEOXYRIBONUCLEIC ACIDS</subject><subject>DOSAGE</subject><subject>EBOLA VIRUS</subject><subject>EFFICACY</subject><subject>FILOVIRUS</subject><subject>INFECTIOUS DISEASES</subject><subject>LABORATORY ANIMALS</subject><subject>LETHALITY</subject><subject>MARBURG</subject><subject>Medicine and Medical Research</subject><subject>MICE</subject><subject>Microbiology</subject><subject>MORPHOLINE</subject><subject>PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS ANTISENSE PHOSPHORODIAMIDATE OLIGOMERS</subject><subject>PMO(PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS)</subject><subject>PROTECTION</subject><subject>RINGS</subject><subject>THERAPY</subject><subject>VACCINES</subject><subject>VIRUSES</subject><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2006</creationdate><recordtype>report</recordtype><sourceid>1RU</sourceid><recordid>eNqFi70KwjAURrM4iPoGDvcFHCS1e9CKokIH6RrS_NiL8UaaK76-EdydPjjnfFOhu1Zu4ETJ3l16ExxpwB45Q9OnaKDD8ZVBPZ4RA1rDmAgMOWjHxN6WTN0MUmY4ex5MLPdQ8LdCggtaPxeTYGL2i9_OxHLfXLeHlWO0OjOSZ612qqpkva7lH_0Ba0Y4wA</recordid><startdate>200603</startdate><enddate>200603</enddate><creator>Enterlein, Sven</creator><creator>Warfield, Kelly L</creator><creator>Swenson, Dana L</creator><creator>Stein, David A</creator><creator>Smith, Jeffrey L</creator><creator>Gamble, C S</creator><creator>Kroeker, Andrew D</creator><creator>Iversen, Patrick L</creator><creator>Bavari, Sina</creator><creator>Muehlberger, Elke</creator><scope>1RU</scope><scope>BHM</scope></search><sort><creationdate>200603</creationdate><title>VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice</title><author>Enterlein, Sven ; Warfield, Kelly L ; Swenson, Dana L ; Stein, David A ; Smith, Jeffrey L ; Gamble, C S ; Kroeker, Andrew D ; Iversen, Patrick L ; Bavari, Sina ; Muehlberger, Elke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-dtic_stinet_ADA4436163</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2006</creationdate><topic>AMPLIFICATION</topic><topic>ANALOGS</topic><topic>ANATOMICAL MODELS</topic><topic>Anatomy and Physiology</topic><topic>ANTISENSE THERAPY</topic><topic>ANTIVIRAL</topic><topic>ARBOVIRUSES</topic><topic>CELLS(BIOLOGY)</topic><topic>CHEMICAL AGENTS</topic><topic>CULTURES(BIOLOGY)</topic><topic>DEOXYRIBONUCLEIC ACIDS</topic><topic>DOSAGE</topic><topic>EBOLA VIRUS</topic><topic>EFFICACY</topic><topic>FILOVIRUS</topic><topic>INFECTIOUS DISEASES</topic><topic>LABORATORY ANIMALS</topic><topic>LETHALITY</topic><topic>MARBURG</topic><topic>Medicine and Medical Research</topic><topic>MICE</topic><topic>Microbiology</topic><topic>MORPHOLINE</topic><topic>PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS ANTISENSE PHOSPHORODIAMIDATE OLIGOMERS</topic><topic>PMO(PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS)</topic><topic>PROTECTION</topic><topic>RINGS</topic><topic>THERAPY</topic><topic>VACCINES</topic><topic>VIRUSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Enterlein, Sven</creatorcontrib><creatorcontrib>Warfield, Kelly L</creatorcontrib><creatorcontrib>Swenson, Dana L</creatorcontrib><creatorcontrib>Stein, David A</creatorcontrib><creatorcontrib>Smith, Jeffrey L</creatorcontrib><creatorcontrib>Gamble, C S</creatorcontrib><creatorcontrib>Kroeker, Andrew D</creatorcontrib><creatorcontrib>Iversen, Patrick L</creatorcontrib><creatorcontrib>Bavari, Sina</creatorcontrib><creatorcontrib>Muehlberger, Elke</creatorcontrib><creatorcontrib>PHILIPPS UNIV MARBURG (GERMANY)</creatorcontrib><collection>DTIC Technical Reports</collection><collection>DTIC STINET</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Enterlein, Sven</au><au>Warfield, Kelly L</au><au>Swenson, Dana L</au><au>Stein, David A</au><au>Smith, Jeffrey L</au><au>Gamble, C S</au><au>Kroeker, Andrew D</au><au>Iversen, Patrick L</au><au>Bavari, Sina</au><au>Muehlberger, Elke</au><aucorp>PHILIPPS UNIV MARBURG (GERMANY)</aucorp><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><btitle>VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice</btitle><date>2006-03</date><risdate>2006</risdate><abstract>Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
Pub. in Antimicrobial Agents and Chemotherapy,v50 n3, p984-993, Mar 2006.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_dtic_stinet_ADA443616 |
source | DTIC Technical Reports |
subjects | AMPLIFICATION ANALOGS ANATOMICAL MODELS Anatomy and Physiology ANTISENSE THERAPY ANTIVIRAL ARBOVIRUSES CELLS(BIOLOGY) CHEMICAL AGENTS CULTURES(BIOLOGY) DEOXYRIBONUCLEIC ACIDS DOSAGE EBOLA VIRUS EFFICACY FILOVIRUS INFECTIOUS DISEASES LABORATORY ANIMALS LETHALITY MARBURG Medicine and Medical Research MICE Microbiology MORPHOLINE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS ANTISENSE PHOSPHORODIAMIDATE OLIGOMERS PMO(PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS) PROTECTION RINGS THERAPY VACCINES VIRUSES |
title | VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A01%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-dtic_1RU&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.btitle=VP35%20Knockdown%20Inhibits%20Ebola%20Virus%20Amplification%20and%20Protects%20Against%20Lethal%20Infection%20in%20Mice&rft.au=Enterlein,%20Sven&rft.aucorp=PHILIPPS%20UNIV%20MARBURG%20(GERMANY)&rft.date=2006-03&rft_id=info:doi/&rft_dat=%3Cdtic_1RU%3EADA443616%3C/dtic_1RU%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |